CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 70% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Medivir (MVIR B) designs innovative and high-end pharmaceuticals aimed to treat cancer and related diseases. The company is focused on nucleotide science and protease research. The development is conducted both in-house and along with partners. The products designed within the strategic partnership are MIV-802, Xerclear, Simprevir Olysio. The most prominent internal products are Remetinostat, MIV-711, Birinapant, MIV-818, MIV-323. Apart from the European region, the company operates in the American, Canadian and Japanese markets. The company’s stock is listed on the NASDAQ Stockholm. To catch up with the latest Medivir share price, follow Capital.com.
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.